Daiichi Sankyo has filed a patent for injectable compositions that can be added to parenteral nutrition. The patent claims a stable injectable composition containing specific amounts of zinc, copper, selenium, and manganese per 1 mL of the composition. The composition also excludes or limits the presence of chromium, aluminum, and iron. Methods of preparation and use are also included in the patent. GlobalData’s report on Daiichi Sankyo gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Daiichi Sankyo, Cancer treatment biomarkers was a key innovation area identified from patents. Daiichi Sankyo's grant share as of September 2023 was 43%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20230302047A1) describes an injectable composition that can be used to maintain plasma trace elements in patients. The composition consists of water and a specific amount of selenium, with no or limited amounts of chromium, aluminum, and iron. The patent claims that the injectable composition contains between 4 µg and 90 µg of selenium per 1 mL of the composition.
The patent also mentions that the injectable composition can have a pH ranging from 1.0 to 5.0. Additionally, the composition may contain nitric acid as an additional component. The patent further specifies that the injectable composition can be suitable for administration to adult, pediatric, or neonatal patients.
The patent claims also provide variations of the injectable composition, such as different amounts of selenium, pH ranges, and the inclusion of nitric acid. The patent mentions that the selenium used in the composition is elemental selenium derived from selenious acid.
Furthermore, the patent states that the injectable composition can be contained in vials of various volumes, including 1 mL, 2 mL, 3 mL, 5 mL, or 10 mL.
The patent also includes information about the permitted daily limits (PDL) of certain elements in the injectable composition. These limits specify that the composition should not exceed certain amounts of cadmium, lead, arsenic, mercury, cobalt, vanadium, nickel, thallium, gold, palladium, iridium, osmium, rhodium, ruthenium, silver, platinum, lithium, antimony, barium, molybdenum, tin, chromium, aluminum, boron, calcium, iron, potassium, magnesium, sodium, tungsten, and silicon.
In summary, the patent describes an injectable composition containing water and selenium, with limited or no amounts of chromium, aluminum, and iron. The composition can have different variations in terms of selenium content, pH range, and the inclusion of nitric acid. It can be suitable for administration to patients of different age groups, and it can be contained in vials of various volumes. The patent also specifies the permitted daily limits for certain elements in the composition.
To know more about GlobalData’s detailed insights on Daiichi Sankyo, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
